Donor White Blood Cell Infusion in Treating Patients With Metastatic or Unresectable Cancer
|ClinicalTrials.gov Identifier: NCT00607802|
Recruitment Status : Withdrawn
First Posted : February 6, 2008
Last Update Posted : January 19, 2017
RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with cancer.
PURPOSE: This clinical trial is studying the side effects of donor white blood cell infusion in treating patients with metastatic or unresectable cancer.
|Condition or disease||Intervention/treatment||Phase|
|Unspecified Adult Solid Tumor, Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific||Biological: leukocyte therapy Genetic: polymerase chain reaction||Not Applicable|
- Determine the safety of white blood cell infusion in patients with metastatic or unresectable cancer.
- Determine the efficacy of this therapy in these patients.
OUTLINE: Patients receive allogeneic white blood cell infusions once daily for 5-10 infusions.
Patients undergo blood sample collection periodically for correlative laboratory studies. The samples are evaluated by in vitro white cell kill assay before the first infusion, immediately after the first infusion, on day 2, and then immediately after the last infusion to assess in vitro cancer cell killing activity. Chimerism studies are performed before the first infusion, immediately after the first infusion, and then on days 2 and 7. Complete chimerism is assayed by short tandem repeat analysis using PCR. Patients with readily accessible tumor tissue (e.g., cervical or axillary lymph nodes or subcutaneous tumor nodules) may also undergo biopsy during the first week of treatment to demonstrate the presence or absence of tumor infiltrating granulocytes.
After completion of study therapy, patients are followed periodically for 3 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Official Title:||White Cell Transfer as Cancer Therapy|
- Response (complete response, partial response, stable disease, or disease progression)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00607802
|Study Chair:||Zheng Cui, MD, PhD||Wake Forest University Health Sciences|